Pyxis Oncology, Inc.

US$1.66As of Sun 8 Nov 2026, 12:00 UTC
NASDAQ:PYXSHealthcare
Country USA
PE (Fwd) •••
TSR 5Y CAGR (33.97%)
Div yield —
ROE (157.51%)
Biotechnology
Beta (5Y) 1.41
PE TTM —
TSR TTM (53.37%)
Mkt cap US$198.3M
ROIC (74.58%)
SE Grade™
Value
Quality
Moat
Consensus
Reference
$1.74
4.63%
(63.74%)
Hold 1|9|2|5|2
4Q25
1Q26
2Q26
3Q26
Earnings per share$
0.03
0.04
0.04
0.04
8.86%
9.31%
8.12%
18.33%
Revenue$M
9.277
9.666
9.573
9.647
7.26%
12.07%
7.64%
9.24%
Peers (US$198.3M)
Cap (US$)
PE
202.5M
—
196.9M
—
Capital
TTM
5Y
10Y
Leveragex
0.203
0.584
0.568
EBIT/Intx
0.111
0.813
1.050
Own earn%
(163.06)
(35.56)
(34.67)
Sh yield%
55.14
28.72
29.16
Owners
Insiders/Inst%
14.31
52.44
Short interest%
2.01
SBC / revenue%
4.43
Record
10Y
Profitable years
10/10
Revenue growth years
10/10
EPS growth years
10/10
Dividend streakyrs
10
Op margin range%
24–33
$1 testx
0.0
Incr. ROIC%
−1